Toronto, Ontario, October 3, 2018 — Verity Pharmaceuticals Inc., a specialty pharmaceutical company, is pleased to announce an exclusive promotion agreement with the Canadian subsidiary of Bausch Health Companies Inc. for Phenazo®(phenazopyridine hydrochloride tablets) in 100mg and 200mg strengths. Under the terms of the agreement, the Canadian subsidiary of Bausch Health Companies Inc. will provide Verity the rights to promote Phenazo® within the Canadian healthcare community.

Phenazo® is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts resulting from irritation of the mucosa of the lower urinary tract caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. Phenazopyridine is compatible with antimicrobial therapy and can help relieve pain and discomfort during the interval before antimicrobial therapy controls the infection.[i]

The terms of the agreement are undisclosed.

“We are pleased and excited to collaborate with the Canadian subsidiary of Bausch Health Companies Inc. on the reintroduction of the Phenazo® brand in Canada. This will enable physicians to provide a safe and effective treatment for patients with urinary tract pain and discomfort. This exemplifies Verity’s focus on fulfilling unmet medical needs within the Canadian healthcare community” – Howard Glase, CEO Verity Pharma.

Typically prescribed for pain caused by Urinary Tract Infections (UTIs), Phenazo® can also be used to treat patients suffering from pain caused by Interstitial Cystitis (IC), Chronic pelvic pain syndrome (CPPS), prostatitis as well as post endoscopic and catheterization irritations.

“For the past decade patients have had to resort to either travelling to the U.S. to get phenazopyridine, or simply biting the bullet and doing without. Occasionally, patients have been able to purchase active ingredients from compounding pharmacies. Phenazo® is a Health Canada-approved product that will provide patients with a consistent level of quality not typically seen with compounded drugs. Physicians (and their patients) will be quite relieved to know that this unique agent is available in Canada” – Dr. Neil Fleshner MD, MPH, FRCSC, Verity Scientific Advisory Board.

Verity Pharma is a specialty pharmaceutical company focused on providing therapeutically relevant legacy agents to the Canadian healthcare community. Our mission is to provide access to prescription products that are in short supply or have not yet been made available in Canada. Phenazo® is just one of a number of important Verity product launches lined up for 2019.


[i]Product Monograph